Navigate to Other Sector


Healthcare Newsletter – November 2016

High Continuing Interest in Small Molecule Assets
USFDA’s big biosimilars approvals
Affordability debate intensifies globally
Developed Market Investments Remain Top Priority for Emerging market Drug Makers

Sathguru Foot Print

Biosimilars—how can we realize the $240 Bn Opportunity?

Excerpts from our white paper:

Market Potential: Global market projected to reach $ 240 Bn by 2030 in the optimistic scenario and the Indian domestic market could be north of $ 35 Bn.

Competitive Landscape: Goliath Vs. Goliath Challenge – Late stage regulated market pipelines dominated by MNCs. Intense competition in RoW markets expected to consolidate; More companies expected to break into regulated markets through collaboration models

Critical elements for success:

  • Technology partnerships to accelerate time to market
  • Derisk coinvestment partnerships to break investment barrier for regulated markets
  • Collaborative approaches to accelerate market expansion in India and other RoW markets

Download the complete whitepaper here…

Mandates—ongoing assignments and partnering opportunities

  • Strategic partnerships and exit opportunities for neonate cooler
  • Out licensing – improved version of blockbuster onco drug
  • In-licensing – marketing partnership for an animal vaccine firm
  • Out-licensing – repurposed imaging agent

Contact us to know more…

Show Buttons
Hide Buttons